Pertinent laboratory investigations revealed elevated liver enzymes [ALT 255 U/L (740 U/L), AST 109 U/L (1335 U/L)], markedly increased TBIL [697.55 mol/L (023.0 mol/L)] and DBIL [472.25 mol/L (06.8 mol/L)], reduced albumin [30.67 g/L (4055 g/L)], hypokalemia [3.36 mmol/L (3.55.3 mmol/L)], and mild hyponatremia [136.3 mmol/L (137.0147.0 mmol/L)]
For more on how compounding pharmacies are regulated, the FDAs human drug compounding guidance outlines the standards that apply to the pharmacies we work with
Oral submucous fibrosis: pathogenesis and therapeutic approaches
Regulatory and safety status: TA-1 is pending FDA review and not currently approved for use in humans
I suspect as my dose increases, Im gonna feel a lot less incline to over eat
I often broke up this dose into two parts, half in the morning and half in the late afternoon